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A B S T R A C T
Antimicrobial resistance is an increasingly important global health threat and the use of antimicrobial
agents is a key risk factor in its development. This study describes antimicrobial agent prescription (AAP)
patterns over a 2 year period using electronic health records (EHRs) from booked consultations in a
network of 457 sentinel veterinary premises in the United Kingdom. A semi-automated classiﬁcation
methodology was used to map practitioner deﬁned product codes in 918,333 EHRs from 413,870 dogs and
352,730 EHRs from 200,541 cats, including 289,789 AAPs. AAP as a proportion of total booked
consultations was more frequent in dogs (18.8%, 95% conﬁdence interval, CI, 18.2–19.4) than cats (17.5%,
95% CI 16.9–18.1). Prescription of topical antimicrobial agents was more frequent in dogs (7.4%, 95% CI
7.2–7.7) than cats (3.2%, 95% CI 3.1–3.3), whilst prescription of systemic antimicrobial agents was more
frequent in cats (14.8%, 95% CI 14.2–15.4) than dogs (12.2%, 95% CI 11.7–12.7). A decreasing temporal
pattern was identiﬁed for prescription of systemic antimicrobial agents in dogs and cats. Premises which
prescribed antimicrobial agents frequently for dogs also prescribed frequently for cats. AAP was most
frequent during pruritus consultations in dogs and trauma consultations in cats. Clavulanic acid
potentiated amoxicillin was the most frequently prescribed antimicrobial agent in dogs (28.6% of
prescriptions, 95% CI 27.4–29.8), whereas cefovecin, a third generation cephalosporin, was the most
frequently prescribed antimicrobial agent in cats (36.2%, 95% CI 33.9–38.5). This study demonstrated
patterns in AAP over time and for different conditions in a population of companion animals in the United
Kingdom.
© 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Antimicrobial resistance (AMR) is widely recognised as an
increasingly important global health threat.1,2,3,4 Evidence of
transmission of bacterial resistance amongst human beings,
livestock (Cuny et al., 2015) and companion animals1 (Zhang
et al., 2016) demonstrates the necessity of a ‘one health’ approach
to preserve treatment efﬁcacy.2 Although use of antimicrobial
agents selects for and promotes transfer of resistance (Rantala
et al., 2004; Magalhaes et al., 2010; Cantón and Bryan, 2012), data
on antimicrobial agent prescription (AAP) to date are limited in
animals.
Antimicrobial agents are frequently prescribed in dogs and cats
(Mateus et al., 2011; Radford et al., 2011; Buckland et al., 2016), and
there is evidence of development of resistance in response to
treatment1 (Trott et al., 2004), and transmission of antimicrobial
resistant isolates between human beings and pets (Johnson et al.,
* Corresponding author.
E-mail address: D.A.Singleton@liverpool.ac.uk (D.A. Singleton).
1 Winner of the 2016 Postgraduate Student Inspiration Award presented by the
UK Kennel Club.
1 See: http://www.ema.europa.eu/docs/en_GB/document_library/Scientiﬁc_gui-
deline/2015/01/WC500181642.pdf. (Accessed 15 July 2016).
2 See: https://www.gov.uk/government/publications/uk-one-health-report-
antibiotics-use-in-humans-and-animals. (Accessed 15 July 2016).
3 See: http://amr-review.org/home. (Accessed 15 July 2016).
4 See: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.
pdf. (Accessed 15 July 2016).
http://dx.doi.org/10.1016/j.tvjl.2017.03.010
1090-0233/© 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2008a,b; Zhang et al., 2016). Speciﬁc guidance for practice level
prescription policies have been published5,6 (Beco et al., 2013a,b);
however, there is a need to understand how these are being applied
in practice.
Data on human AAP in the United Kingdom (UK) are freely
available, in part because of a national health system.7 For animals,
the Veterinary Medicines Directorate (VMD) is constructing a
central body collating data on AAP for the UK; however data
currently available cannot identify antimicrobial agents adminis-
tered under the cascade prescribing system, which species they
have been prescribed to, practice level prescription variability or
why the antimicrobial agents were prescribed.8 Advances in
veterinary health informatics provides opportunities to ﬁll this
gap, particularly for companion animals where Electronic Health
Records (EHR) are most developed and accessible (O’Neill et al.,
2014a).
Early studies of companion animal AAP in the UK were limited
in size, but have consistently pointed to frequent use of b-lactams
(Mateus et al., 2011; Radford et al., 2011). More recently, using a
much larger data set, 25% of dogs and 21% of cats seen at veterinary
practices received at least one AAP over a 2 year period (2012–
2014), the most frequent being penicillins and cephalosporins
(Buckland et al., 2016). Whilst such ‘big data’ studies have started
to report on AAP, this study aims to describe a near real-time, on-
going, AAP surveillance system from a diverse range of veterinary
premises (n = 457) that also consider AAP in a broad range of
practitioner deﬁned clinical presentations.
Materials and methods
Data collection
The Small Animal Veterinary Surveillance Network (SAVSNET)
collected EHRs in near real-time from booked consultations in
volunteer UK veterinary practices (1 April 2014–31 March 2016). A
full description of the data collection protocol has been described
by Sánchez-Vizcaíno et al. (2015). A practice (n = 216) was deﬁned
as a single business, whereas premise(s) (n = 457) included all
branches that form a practice (see Appendix: Supplementary
Fig. 1). Before submitting each consultation to SAVSNET, the
practitioner selected one of 10 main presenting complaints (MPCs),
consisting of a pre-determined list grouped into healthy, unhealthy
and post-operative categories (see Appendix: Supplementary
Table 1). The EHR further included product codes as text strings
deﬁned by individual practices.
Antimicrobial agent identiﬁcation
The product codes of the EHR were utilised to identify AAP. A set
of 52,267 codes (extracted 26 August 2015) were manually
categorised. Pharmaceutical products were deﬁned with reference
to the VMD’s Product Information Database for veterinary
authorised products, and the electronic Medicines Compendium
(Datapharm Communications) for human authorised products. An
identifying string was ascribed to each antimicrobial agent product
and was used to identify the product code. This process was
reiterated until all pharmaceutical and non-pharmaceutical
product codes were classiﬁed to further validate antimicrobial
agent identiﬁcation. When applied to the complete list of 95,709
codes (extracted 31 March 2016), 416 antimicrobial agent
identifying strings were utilised.
Where possible, product codes for antimicrobial agents were
further characterised to speciﬁc species authorisation and
administration by systemic (oral or injectable) or topical (topical,
aural or ocular) routes. Whilst not all products were authorised for
human use at the time of the study, we considered all
ﬂuoroquinolones, macrolides and third generation cephalosporins
as highest priority critically important antimicrobial agents
(HPCIA), as deﬁned by the World Health Organization (WHO).9
Statistical analysis
Consultation and prescription-level proportions and conﬁdence
intervals were calculated to adjust for clustering (bootstrap
method, n = 5000 samples) within premises and at animal level
within practices.10 Pearson correlations (t-test to reject null
hypothesis) were performed to explore prescription frequency
for dog and cat total, systemic and topical AAP as a proportion of
total submitted consultations for each premises. Paired t-tests with
Bonferroni corrections were used for a matched pairs premises
level sample to investigate total, systemic and topical AAP as a
proportion of total submitted consultations for each MPC.
A mixed effects binomial regression model, incorporating
practice and premise as random effects, was utilised to examine
quarterly variation in total, systemic and topical canine and feline
AAP as a proportion of total consultations. The variable time was
categorised as an ordinal variable into quarters of the year (Q1, Q2,
Q3 and Q4) and included as a ﬁxed effect. Quarter was codiﬁed
using two contrasting coding systems: (1) an orthogonal polyno-
mial method11 to analyse for overall trend (see Appendix:
Supplementary Table 2); and (2) a backward differencing
method12 to investigate quarter-by-quarter variation in a back-
ward pairwise manner (e.g. Q1 2016 compared with Q4 2015). A
further model was ﬁtted for canine and feline HPCIA prescription
as a proportion of total AAP. A likelihood ratio test (LRT) indicated
that including practice and premise as random effects in all models
provided the best ﬁt. Statistical signiﬁcance was deﬁned as P < 0.05
and all analyses were carried out using R (version 3.2.3).13
Results
A total of 918,333 canine EHRs (from 413,870 dogs) and 352,730
feline EHRs (from 200,541 cats) were obtained from 216 veterinary
practices (457 premises) from 1 April 2014 to 31 March 2016.
Consultation and animal level
The percentage of consultations where at least one antimicro-
bial agent was prescribed (AAPC) was signiﬁcantly greater for dogs
(18.8%, 95% conﬁdence interval, CI, 18.2–19.4) than cats (17.5%, 95%
CI 16.9–18.1). Systemic AAPC was signiﬁcantly less frequent in dogs
(12.2%, 95% CI 11.7–12.7) than cats (14.8%, 95% CI 14.2–15.4),
representing 64.9% (95% CI 63.8–66.0) and 84.5% (95% CI
83.9–85.2) of total canine and feline AAPC, respectively (paired
t-test; P < 0.001). Topical AAPC was signiﬁcantly more frequent in
5 See: http://www.bsava.com/Resources/PROTECT.aspx. (Accessed 4 October
2016).
6 See: http://www.fecava.org/content/guidelines-policies. (Accessed 15 July
2016).
7 See: http://ﬁngertips.phe.org.uk. (Accessed 15 July 2016).
8 See: https://www.gov.uk/government/publications/veterinary-antimicrobial-
resistance-and-sales-surveillance-2014. (Accessed 15 July 2016).
9 See: http://www.who.int/foodsafety/publications/antimicrobials-fourth/en/.
(Accessed 13 February 2017).
10 See: http://cran.r-project.org/package=aod. (Accessed 11 October 2016).
11 See: http://www.ats.ucla.edu/stat/r/library/contrast_coding.htm#ORTHOGO-
NAL. (Accessed 11 October 2016).
12 See: http://www.ats.ucla.edu/stat/r/library/contrast_coding.htm#backward.
(Accessed 11 October 2016).
13 See: http://www.R-project.org/. (Accessed 23 November 2016).
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dogs (7.4% of consultations, 95% CI 7.2–7.7) than cats (3.2%, 95% CI
3.1–3.3), representing 39.6% (95% CI 38.5–40.6) and 18.3% (95% CI
17.7–19.0) of AAPC, respectively (P < 0.001). Dogs and cats were co-
prescribed systemic and topical antimicrobial agents in 0.87% (95%
CI 0.84–0.94) and 0.59% (95% CI 0.54–0.64) of total consultations,
respectively. Signiﬁcant positive correlations were found between
dogs and cats at premise level for total (0.62, 95% CI 0.56–0.67,
P < 0.001), systemic (0.61, 95% CI 0.54–0.66, P < 0.001) and topical
(0.21, 95% CI 0.12–0.30, P < 0.001) AAPC (Fig. 1).
Fig. 2 shows AAPC categorised by quarter. A signiﬁcant negative
linear trend was observed for canine total and systemic AAPC, and
feline total, systemic and topical AAPC (P < 0.001; see Appendix:
Supplementary Table 3). A signiﬁcant negative trend by quarter
was observed for canine topical AAPC (P < 0.001). Results of
quarter-by-quarter comparison models can be found in Supple-
mentary Table 4 (see Appendix).
Over the 2 year period, at the animal level, 28.4% (95% CI 27.2–
29.7) of dogs were prescribed an antimicrobial agent, compared
with 23.3% (95% CI 22.3–24.4) of cats. When route of administra-
tion was considered, 19.6% (95% CI 18.4–20.7) of dogs and 20.0%
(18.9–21.0) of cats were prescribed a systemic antimicrobial agent,
and 12.9% (95% CI 12.3–13.5) of dogs and 5.0% (95% CI 4.7–5.2) of
cats were prescribed a topical antimicrobial agent.
Total AAPC was 35.5% (95% CI 34.5–36.5) of unhealthy dogs,
35.1% (95% CI 34.1–36.1) of unhealthy cats, 7.4% (95% CI 6.7–8.0) of
healthy dogs and 5.5% (95% CI 4.9–6.2) of healthy cats. Systemic
AAPC was more frequent in unhealthy cats (30.5%, 95% CI 29.5–
31.5) than unhealthy dogs (24.1%, 95% CI 23.1–25.0). The MPCs with
the highest frequencies of AAPC were pruritus in dogs (51.0%, 95%
CI 49.8–52.2) and trauma in cats (53.5%, 95% CI 52.1–54.8).
Antimicrobial agents were prescribed in a signiﬁcantly greater
proportion of dogs than cats for gastroenteric (P < 0.001), pruritus
(P < 0.001), kidney disease (P < 0.001), other unwell (P = 0.012),
vaccination (P < 0.001), other healthy (P = 0.001) and post-opera-
tive (P = 0.003) consultations. Cats were prescribed antimicrobial
agents signiﬁcantly more frequently than dogs for respiratory
(P < 0.001) and trauma (P < 0.001) consultations. Full results are
presented in Tables 1 and 2.
Level of antimicrobial agent prescription
A total of 218,700 canine and 71,089 feline AAPs were made
from 215 practices (455 premises) in the UK.
Authorisation
For systemic AAP, 90.0% (95% CI 88.5–91.4) of canine and 92.9%
(95% CI 91.7–94.1) of feline AAPs were species authorised, with
0.6% (95% CI 0.2–0.9) and 5.2% (95% CI 4.0–6.5) authorised in other
veterinary species; of these, 8.2% (95% CI 7.0–9.4) and 1.7% (95% CI
1.4–2.1) were human authorised, 0.9% (95% CI 0.4–1.3) and 0.05%
(95% CI 0.03–0.07) were dual generic and 0.4% (95% CI 0.1–0.6) and
0.04% (95% CI 0.00–0.09) were expired or of unknown authorisa-
tion, respectively. Metronidazole was the most frequently pre-
scribed human authorised systemic antimicrobial agent in dogs
(96.7% of human authorised systemic AAP, 95% CI 95.3–98.1) and
cats (94.2%, 95% CI 92.1–96.3).
Class of antimicrobial agent
Clavulanic acid potentiated amoxicillin was the most frequently
prescribed antimicrobial agent in dogs (28.6% of total AAP, 95% CI
27.4–29.8) and cefovecin was the most frequently prescribed
antimicrobial agent in cats (36.2%, 95% CI 33.9–38.5) (Tables 3, 4
and 5). Fusidic acid was the most frequently prescribed topical
antimicrobial agent in dogs (44.3% of topical AAP, 95% CI 43.1–45.4)
and cats (55.1%, 95% CI 53.6–56.6).
Highest priority critically important antimicrobial agents
Canine and feline HPCIA prescriptions were 5.4% (95% CI
4.6–6.1) and 39.2% (95% CI 36.8–41.7) of total AAPs respectively. On
consideration of temporal trend, for canine HPCIA prescription, a
signiﬁcant positive cubic trend was noted (P < 0.001). Similarly, in
cats, a signiﬁcant positive linear trend was found (P < 0.001) (see
Appendix: Supplementary Tables 3 and 4). The most frequently
prescribed HPCIAs in dogs were ﬂuoroquinolones and in cats was
cefovecin, a third generation cephalosporin (Fig. 3).
Main presenting complaint
Total canine and feline AAPs summarised by MPCs are shown in
Supplementary Tables 5 and 6 (see Appendix). Clavulanic acid
potentiated amoxicillin was the most commonly prescribed
antimicrobial agent in dogs for respiratory conditions, trauma,
tumours and kidney disease, as well as other unwell,
post-operative and other healthy MPCs. In cats, cefovecin was
the most commonly prescribed antimicrobial agent for respiratory
conditions, pruritus, trauma, tumours and kidney disease, as well
as other unwell, post-operative and other healthy MPCs.
Discussion
In this study, EHRs were used to describe AAP in a large
population of companion animal veterinary premises. Quantitative
differences in AAP were found between dogs and cats, and
according to MPC. AAPC decreased signiﬁcantly over the course of
the study in this population of animals.
Fig. 1. Comparison of canine and feline antimicrobial agent prescription as a percentage of total consultations (AAPC) by premises (n = 457) split by (a) total, (b) systemic and
(c) topical antimicrobial agent prescription.
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Fig. 2. Comparison of (a) canine (n = 918,333 electronic health records) and (b) feline (n = 352,730) total, systemic and topical antimicrobial agent prescription as a percentage
of total consultations (95% conﬁdence interval) by quarter (Q2 2014–Q1 2016).
Table 1
Canine antimicrobial agent prescription percentage (total, systemic and topical) by practitioner badged main presenting complaint calculated from total number of
consultations for each category in a network of United Kingdom small animal veterinary premises.
Main presenting complaint Dog
Number (%) of EHRsa Total Systemic Topical
% 95% CIb % CIb % CIb
Pruritus 62,655 (6.8) 51.0 49.8–52.2 25.5 24.2–26.9 30.0 29.0–31.0
Respiratory 14,359 (1.6) 42.2 40.5–44.0 40.4 38.7–42.2 2.7 2.2–3.2
Gastroenteric 38,954 (4.2) 39.4 37.0–41.7 38.2 35.8–40.6 1.7 1.2–2.2
Trauma 58,033 (6.3) 26.7 25.5–27.9 21.3 20.3–22.4 6.2 5.8–6.6
Kidney disease 2607 (0.28) 29.1 26.6–31.7 26.8 24.3–29.3 3.0 2.2–3.7
Tumour 20,938 (2.3) 22.0 21.1–23.0 17.5 16.7–18.3 5.4 5.0–5.8
Other unwell 156,197 (17.0) 32.8 31.8–33.8 20.3 19.5–21.2 13.9 13.4–14.5
Post-operative 98,753 (10.8) 13.0 12.2–13.8 9.9 9.3–10.5 3.5 3.1–3.8
Vaccination 277,246 (30.2) 4.3 3.9–4.7 1.4 1.1–1.7 3.0 2.8–3.2
Other healthy 188,582 (20.6) 11.8 10.7–13.0 7.0 6.1–7.8 5.3 4.8–5.9
a Number (%) of electronic health records (EHRs). Relative occurrence of badged consultations as a frequency and as a percentage of total consultations.
b 95% Conﬁdence interval.
Table 2
Feline antimicrobial agent prescription percentage (total, systemic and topical) by practitioner badged main presenting complaint calculated from total number of
consultations for each category in a network of United Kingdom small animal veterinary premises.
Main presenting complaint Cat
Number (%) of EHRsa Total Systemic Topical
% 95% CIb % 95% CIb % 95% CIb
Pruritus 13,749 (3.9) 33.5 31.9–35.2 24.9 23.3–26.6 10.3 9.5–11.1
Respiratory 7681 (2.2) 52.0 49.8–54.3 59.9 47.6–52.2 5.3 4.6–5.9
Gastroenteric 11,206 (3.2) 29.8 27.4–31.8 28.9 26.7–31.1 1.0 0.7–1.4
Trauma 22,796 (6.5) 53.5 52.1–54.8 50.1 48.8–51.4 4.3 4.0–4.7
Kidney disease 4009 (1.1) 19.6 17.9–21.3 18.9 17.2–20.6 0.7 0.5–1.0
Tumour 5330 (1.5) 21.3 19.8–22.7 19.8 18.3–21.3 1.7 1.4–2.0
Other unwell 72,189 (20.5) 30.5 29.5–31.6 24.9 23.9–26.0 6.5 6.3–6.8
Post-operative 32,136 (9.1) 11.1 10.0–11.9 9.6 8.7–10.6 1.7 1.4–2.0
Vaccination 115,394 (32.6) 2.5 2.2–2.8 1.4 1.2–1.6 1.2 1.1–1.3
Other healthy 68,236 (19.4) 10.5 9.1–11.9 8.4 7.1–9.6 2.4 2.1–2.7
a Number (%) of electronic health records (EHRs). Relative occurrence of badged consultations as a frequency and as a percentage of total consultations.
b 95% Conﬁdence interval.
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Broadly similar levels of total AAP were found in dogs and cats.
However, when route of administration was considered, dogs were
signiﬁcantly more likely to be prescribed topical antimicrobial
agents than cats, whereas cats were signiﬁcantly more likely to be
prescribed systemic antimicrobial agents than dogs. Such differ-
ences may reﬂect an increased prevalence of pruritus (and other
dermatological diseases) in dogs compared to cats (Sánchez-
Vizcaíno et al., 2016). They may also reﬂect the challenge of giving
oral and topical medication to cats when compared to injectable
antimicrobial agents (Burke et al., 2016).
Using data derived from EHRs, it was not possible to determine
whether individual prescriptions were appropriate, nor whether
the overall frequency of AAP in this population was appropriate.
However, there was a signiﬁcant reduction in canine and feline AAP
within this population over the 2 years of the study. Whether this
reﬂects the success of awareness campaigns is not known.14,15 It is
possible that changes in AAP might reﬂect changes in other aspects
of veterinary activity, such as vaccination. Furthermore, previous
human AAP surveillance has noted short-term temporal variability
that is not necessarily reﬂective of longer term patterns.16 As a
consequence, there is a need to for ongoing monitoring of AAP.
Buckland et al. (2016) found that 25.2% of dogs and 20.6% of cats
in the UK received systemic antimicrobial agents from 2012 to
2014. Whilst our results (2014–2016) were lower for dogs (19.6%),
they were similar for cats (20.0%). In a smaller study conducted in
the UK in 2010 (Radford et al., 2011), the proportion of
consultations involving unhealthy animals where systemic anti-
microbial agents were prescribed was 35.1% for dogs and 48.5% for
cats. In our study, these values were lower (unhealthy dogs 24.1%,
unhealthy cats 30.5%). It is unclear whether differences between
these studies reﬂect a reduction in frequency of prescription of
systemic antimicrobial agents, or are related to population
differences or methods used to identify AAP.
Considerable variation in AAPs according to premise was
identiﬁed in our study, as well as in the previous study by Radford
et al. (2011). Premises that prescribed antimicrobial agents more
frequently to dogs also tended to prescribe more frequently to cats.
Such a correlation may be explained by geographical variation in
risk (perceived or actual), either for AMR or for bacterial infections
capable of infecting both species. Other complex factors, extending
beyond the risk of antimicrobial agent responsive disease, can
inﬂuence AAP decisions, such as clinical experience, perceived
owner and/or pet compliance and practice policy (Hughes et al.,
2012; Mateus et al., 2014).
It is not surprising that certain MPCs were more commonly
associated with AAP, suggesting that practitioners believe that the
risk of infection responsive to antimicrobial agents is higher in
certain MPCs. Pruritus in dogs is frequently associated with
bacterial pyoderma (Summers et al., 2014) and was associated with
the most frequent use of topical antimicrobial agents in our study.
However, acute respiratory disease in cats is generally considered
to have a viral origin, although primary bacterial disease has been
described and secondary bacterial infections can increase the
severity of disease (Jacobs et al., 1993). Prescription of antimicro-
bial agents in feline trauma may reﬂect a high frequency of cat bite
abscesses associated with this MPC (Radford et al., 2011; O’Neill
et al., 2014b).
In dogs, clavulanic acid potentiated amoxicillin was the most
frequently prescribed antimicrobial agent, as found in previous
studies (Mateus et al., 2011; Radford et al., 2011; Buckland et al.,
2016). In our study and that of Buckland et al. (2016), cefovecin was
the most frequently prescribed antimicrobial agent in cats, in
contrast to previous studies, where amoxicillin and clavulanic acid
potentiated amoxicillin were more frequently prescribed (Mateus
et al., 2011; Radford et al., 2011). This suggests that there has been a
recent shift in choice of antimicrobial agents for cats. Prescription
of cefovecin was common for MPCs associated with authorised
indications for use, such as pruritus and kidney disease17 (Burke
et al., 2016). However, cefovecin was also prescribed frequently in
MPCs, such as respiratory and gastroenteric disease in cats, where
there was no apparent indication for prescription by the datasheet1
or practice prescribing policy.18,19 It is also possible that relying on
MPCs as declared by veterinary practitioners might fail to include
other clinical conditions found during the same consultation.
Collection and analysis of clinical free text present an opportunity
to characterise each consultation based on clinical signs and
duration, which would provide further information to support the
rationale for any given prescription (Burke et al., 2016).
Although cefovecin is not authorised for human use, it is a third
generation cephalosporin and is classiﬁed as an HPCIA.20,21
Relevant product information sheets state that cefovecin should
be reserved for clinical conditions which have responded poorly, or
are expected to respond poorly, to other classes of antimicrobial
agents.22 In our study, it was not possible to determine to what
extent the use of cefovecin is in compliance with these
Table 3
Percentage breakdown of canine antimicrobial agent prescriptions by antimicrobial
agent class prescribed for total, systemic and topical prescriptions from a network
of United Kingdom small animal veterinary premises.
Antimicrobial agent class Total Systemic Topical
% 95% CIa % 95% CIa % 95% CIa
Aminoglycoside 12.0 11.4–12.6 0.1 0.0–0.2 29.1 28.0–
30.2
Amphenicol 1.9 1.6–2.1 0.0 <0.00 4.5 3.9–5.2
Other antimicrobial
agentb







Fluoroquinolone 4.4 3.6–5.1 4.1 3.1–5.2 4.6 4.0–5.2
Fusidic acid 18.2 17.4–19.0 0.0 <0.00 44.3 43.1–
45.4
Lincosamide 4.7 4.2–5.2 7.9 7.0–8.8 0.0 <0.00
Macrolide 0.2 0.0–0.3 0.3 0.0–0.6 0.0 <0.00
Nitroimidazole 4.7 4.0–5.4 8.0 6.7–9.2 0.0 <0.00
Nitroimidazole-
macrolide
0.8 0.5–1.0 1.3 0.8–1.7 0.0 <0.00
Rifamycin 0.0 <0.00 0.0 <0.00 0.0 <0.00
Sulphonamide 1.5 1.1–1.9 2.5 1.9–3.2 0.0 <0.00
Tetracycline 1.2 1.0–1.3 2.0 1.7–2.2 0.0 0.00–
0.01
a 95% Conﬁdence interval.
b Consists of polymyxin b sulphate; mupirocin; novobiocin; thymol and
bronopol.
14 See: http://www.fecava.org/content/guidelines-policies. (Accessed 15 July
2016).
15 See: http://www.bsava.com/Resources/PROTECT.aspx. (Accessed 4 October
2016).
16 See: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-con-
sumption-europe-esac-net-2012.pdf. (Accessed 26 January 2017).
17 See: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro-
duct_Information/veterinary/000098/WC500062067.pdf. (Accessed 12 December
2016).
18 See: http://www.fecava.org/content/guidelines-policies. (Accessed 15 July
2016).
19 See: http://www.bsava.com/Resources/PROTECT.aspx. (Accessed 4 October
2016).
20 See: http://www.who.int/foodsafety/publications/antimicrobials-fourth/en/.
(Accessed 13 February 2017).
21 See: http://www.noah.co.uk/wp-content/uploads/2016/12/NOAH-brieﬁng-on-
CIAs-07122016.pdf. (Accessed 14 February 2017).
22 See: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro-
duct_Information/veterinary/000098/WC500062067.pdf. (Accessed 12 December
2016).
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Table 4
Percentage breakdown of feline antimicrobial agent prescriptions by antimicrobial agent class prescribed for total, systemic and topical prescriptions from a network of
United Kingdom small animal veterinary premises.
Class of antimicrobial agent Total Systemic Topical
% 95% CIa % 95% CIa % 95% CIa
Aminoglycoside 4.5 4.2–4.8 0.2 0.1–0.3 22.1 20.7–23.6
Amphenicol 1.3 1.1–1.5 0.0 <0.00 6.5 5.6–7.4
Other antimicrobial agentb 2.7 2.4–2.9 0.0 <0.00 13.5 12.4–14.6
b-lactam 70.8 69.3–72.3 87.9 86.1–89.7 0.3 0.0–0.6
Fluoroquinolone 3.0 1.7–4.3 3.1 1.6–4.7 2.5 2.0–3.0
Fusidic acid 10.8 10.2–11.3 0.0 <0.00 55.1 53.6–56.6
Lincosamide 4.1 3.5–4.7 5.2 4.4–5.9 0.0 <0.00
Macrolide 0.05 0.01–0.09 0.07 0.01–0.12 0.0 <0.00
Nitroimidazole 1.3 1.1–1.6 1.6 1.3–2.0 0.0 <0.00
Nitroimidazole-macrolide 0.4 0.2–0.5 0.5 0.3–0.7 0.0 <0.00
Rifamycin 0.0 <0.00 0.0c <0.00 0.0 <0.00
Sulphonamide 0.05 0.03–0.07 0.06 0.03–0.09 0.0 <0.00
Tetracycline 1.1 1.0–1.3 1.4 1.2–1.6 0.0 <0.00
a 95% Conﬁdence interval.
b Polymyxin b sulphate, mupirocin, novobiocin, thymol and bronopol.
c One recorded prescription of rifampicin for systemic administration (authorised for oral administration).
Table 5
Percentage breakdown of b-lactam antimicrobial agent prescription by species and b-lactam sub-categories as a percentage of total and systemic antimicrobial agent
prescriptions from a network of small animal veterinary premises in the United Kingdom.
Class of antimicrobial agent Total prescription Systemic prescription
Dog Cat Dog Cat
% 95% CIa % CIa % CIa % CIa
Amoxicillin 5.3 4.1–6.5 12.5 10.0–15.0 9.0 7.1–10.9 15.3 12.2–18.3
Other b-lactamsb 0.4 0.0–0.8 0.07 0.01–0.13 0.5 0.0–1.3 0.02 0.00–0.05
First generation cephalosporin 8.4 7.8–9.0 0.4 0.3–0.5 14.2 13.2–15.3 0.5 0.4–0.6
Second generation cephalosporin 0.04 0.01–0.07 0.01 0.00–0.02 0.07 0.02–0.12 0.02 0.00–0.03
Third generation cephalosporin 0.9 0.7–1.0 36.2 33.9–38.5 1.5 1.3–1.8 45.1 42.1–48.2
Clavulanic acid potentiated amoxicillin 28.6 27.4–29.8 21.6 19.6–23.6 48.5 46.0–50.9 26.9 24.5–29.3
Penicillin 0.03 0.01–0.05 0.03 0.01–0.05 0.04 0.01–0.07 0.04 0.01–0.06
Total 43.6 70.8 73.8 87.9
a 95% conﬁdence interval.
b Ampicillin and cloxacillin.
Fig. 3. Comparison of (a) canine and (b) feline highest priority ‘critically important antimicrobial agent’ (HPCIA) prescription as a percentage of total antimicrobial agent
prescriptions (95% conﬁdence interval) by quarter (Q2 2014–Q1 2016).
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recommendations. A recent study showed that veterinary sur-
geons prescribing cefovecin rarely justiﬁed its use within the
clinical narrative (Burke et al., 2016). Relative ease of administra-
tion and duration of action, together aiding compliance, may be
important motivating factors for the use of cefovecin in veterinary
practice. We noted considerable variation in prescription of
cefovecin between premises, suggesting that there are differences
in cat populations, presentations or justiﬁcation for veterinary
prescription. We further observed a slight increase in overall HPCIA
prescription in dogs and cats throughout the study, and that many
of the most commonly prescribed antimicrobial agents in both
species are considered to be critically important.23
Whilst such large volumes of data provide new insights into
AAP, the nature of these data have their own inherent limitations.
Quantiﬁcation of AAP relies on practitioners charging for
antimicrobial agents through their practice management software,
which means that any antimicrobial agents not charged for will be
missed. The SAVSNET population of practices is recruited on the
basis of convenience and so cannot necessarily be considered to be
representative of the wider UK population. In order to fully place
ﬁndings in context, there is a need for in depth analysis of the
animal populations monitored. The use of the MPC function allows
all consultations to be coded in real time; variations in individual
interpretation of the MPC case deﬁnition are possible.
Conclusions
AAP frequency decreased from 2014 to 2016 in this population
of dogs and cats in the UK. Additionally, some MPCs were more
likely to be associated with AAP than others, both within and
between the two species. There is considerable variability in AAP
amongst different premises and there is a need to understand
factors that inﬂuence AAP at the individual animal, owner and
premise level, particularly for HPCIAs. To aid responsible use,
SAVSNET provides a mechanism for participating practices to
benchmark their prescription against anonymised peers via an
online portal. This and other studies are now providing the
valuable tools and data that the profession needs to ensure
antimicrobial agents are used responsibly.
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